Abstract
Rectal cancer (RC) is one of the most common cancers worldwide. RC has high morbidity and mortality rates, with locally advanced rectal cancer (LARC) accounting for > 30% of cases. Patients with LARC are routinely treated with neoadjuvant chemoradiotherapy (nCRT) but treatment outcomes vary greatly. It is crucial to predict and evaluate patient response to nCRT as early as possible. Radiomics is a potentially useful and non-invasive tool for clinical applications in different types of cancer including colorectal cancer. Radiomics has recently been used to predict treatment outcomes and many published studies have demonstrated the efficacy of radiomics. This review will discuss the application of radiomics in predicting of LARC response to nCRT and provide new insight for corollary studies.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
